Bracco Affirms ASNC Position Statement Elevating Cardiac PET with Myocardial Blood Flow as Preferred Standard for Coronary Artery Disease

Bracco, the market leader in diagnostic imaging and the pioneer in cardiac positron emission tomography (PET) for more than ...
Medscape

Novel PET Tracer for Perfusion Imaging: What's the Potential?

The emerging advantages of positron-emission tomography (PET) myocardial perfusion imaging (MPI) for coronary artery disease (CAD) diagnosis and assessment of cardiovascular event risk has prompted ...
Business Wire

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...
Becker's Hospital Review

University Hospitals 1st in Ohio to adopt Flyrcado imaging agent

Cleveland-based University Hospitals Harrington Heart & Vascular Institute has become the first site in Ohio to clinically administer Flyrcado for the detection of coronary artery disease and arterial ...
Business Wire

ACC 2025: GE HealthCare announces the U.S. launch of pivotal innovations that will help transform the cardiology care pathway

The much-anticipated Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery disease, ...

XVIVO Perfusion AB: The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal

GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter ...
News Medical

Machine perfusion extends long-distance heart transplant possibilities

In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn't get the organ to a recipient in time.

The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal

GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT ...